Bristol-Myers Squibb (BMY) Gets Morgan Stanley Lower Rating; Harber Asset Management Cut Pdf Solutions (PDFS) Position

Bristol-Myers Squibb Company (NYSE:BMY) Logo

Harber Asset Management Llc decreased Pdf Solutions Inc (PDFS) stake by 10.39% reported in 2017Q4 SEC filing. Harber Asset Management Llc sold 39,814 shares as Pdf Solutions Inc (PDFS)’s stock declined 28.02%. The Harber Asset Management Llc holds 343,399 shares with $5.39M value, down from 383,213 last quarter. Pdf Solutions Inc now has $376.88M valuation. The stock decreased 0.09% or $0.01 during the last trading session, reaching $11.67. About 76,157 shares traded. PDF Solutions, Inc. (NASDAQ:PDFS) has declined 48.74% since April 17, 2017 and is downtrending. It has underperformed by 60.29% the S&P500.

Morgan Stanley decreased Bristol-Myers Squibb (NYSE:BMY)‘s stock to a “Equal-Weight” rating from a “Overweight”. The rating change was issued to investors and clients in a analysts report today.

Since December 12, 2017, it had 1 buy, and 1 insider sale for $85,985 activity. Lynch Thomas J. Jr. sold $335,172 worth of Bristol-Myers Squibb Company (NYSE:BMY) on Tuesday, December 12. Samuels Theodore R. II bought $249,187 worth of stock or 4,000 shares.

Investors sentiment decreased to 0.94 in Q4 2017. Its down 0.09, from 1.03 in 2017Q3. It is negative, as 72 investors sold Bristol-Myers Squibb Company shares while 526 reduced holdings. 106 funds opened positions while 457 raised stakes. 1.11 billion shares or 0.48% more from 1.11 billion shares in 2017Q3 were reported. Alyeska Gp Inc Limited Partnership invested in 590,334 shares. Ingalls Snyder Ltd Liability Corporation reported 0.55% stake. Harris Limited Partnership, Illinois-based fund reported 491,786 shares. Linscomb And Williams has 4,756 shares for 0.02% of their portfolio. Meag Munich Ergo Kapitalanlagegesellschaft Mbh reported 168,221 shares. Gulf Interest National Bank (Uk) Limited invested in 0.4% or 519,055 shares. Jarislowsky Fraser Limited reported 740,957 shares. Natixis has 0.29% invested in Bristol-Myers Squibb Company (NYSE:BMY). Paragon Cap Management Lc has invested 0.08% in Bristol-Myers Squibb Company (NYSE:BMY). Laffer Invs has 0.78% invested in Bristol-Myers Squibb Company (NYSE:BMY) for 50,721 shares. 105,792 are held by Osborne Cap Mgmt Ltd Llc. Renaissance Technology Limited Company has 0.97% invested in Bristol-Myers Squibb Company (NYSE:BMY) for 14.30M shares. Veritable L P stated it has 0.29% in Bristol-Myers Squibb Company (NYSE:BMY). Moreover, Noesis Cap Mangement has 0.13% invested in Bristol-Myers Squibb Company (NYSE:BMY) for 6,277 shares. Ls Inv Advsr Ltd Com has invested 0.34% in Bristol-Myers Squibb Company (NYSE:BMY).

Among 22 analysts covering Bristol-Myers Squibb Company (NYSE:BMY), 8 have Buy rating, 3 Sell and 11 Hold. Therefore 36% are positive. Bristol-Myers Squibb Company has $80 highest and $45 lowest target. $64.18’s average target is 18.68% above currents $54.08 stock price. Bristol-Myers Squibb Company had 79 analyst reports since July 28, 2015 according to SRatingsIntel. As per Monday, December 19, the company rating was upgraded by Jefferies. The rating was maintained by Piper Jaffray with “Hold” on Thursday, October 26. The stock of Bristol-Myers Squibb Company (NYSE:BMY) earned “Hold” rating by Jefferies on Monday, February 26. The firm earned “Outperform” rating on Wednesday, April 26 by Robert W. Baird. The firm has “Hold” rating given on Tuesday, June 14 by Jefferies. Jefferies maintained it with “Hold” rating and $65 target in Tuesday, March 15 report. The rating was maintained by Credit Suisse with “Hold” on Wednesday, August 16. The rating was upgraded by Guggenheim on Wednesday, December 2 to “Buy”. The firm has “Buy” rating by UBS given on Friday, October 6. Barclays Capital maintained the shares of BMY in report on Friday, October 13 with “Equal-Weight” rating.

The stock decreased 7.79% or $4.57 during the last trading session, reaching $54.08. About 34.84M shares traded or 363.08% up from the average. Bristol-Myers Squibb Company (NYSE:BMY) has risen 11.37% since April 17, 2017 and is uptrending. It has underperformed by 0.18% the S&P500.

Bristol-Myers Squibb Company discovers, develops, licenses, makes, markets, and distributes biopharmaceutical products worldwide. The company has market cap of $88.42 billion. The firm offers chemically-synthesized drug and biologic in various therapeutic areas, such as oncology; cardiovascular; immunoscience; and virology comprising human immunodeficiency virus infection . It has a 88.66 P/E ratio. The Company’s products include Empliciti, a humanized monoclonal antibody to treat multiple myeloma; Opdivo, a human monoclonal antibody to treat renal cell carcinoma, non-small cell lung cancer, classical Hodgkin lymphoma, gastric cancer, melanoma, metastatic urothelial carcinoma, and squamous cell carcinoma of the head and neck; Erbitux, an IgG1 monoclonal antibody that blocks the epidermal growth factor receptor; Sprycel, a tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia; and Yervoy, a monoclonal antibody for metastatic melanoma.

Analysts await Bristol-Myers Squibb Company (NYSE:BMY) to report earnings on April, 26 before the open. They expect $0.84 earnings per share, 0.00% or $0.00 from last year’s $0.84 per share. BMY’s profit will be $1.37B for 16.10 P/E if the $0.84 EPS becomes a reality. After $0.68 actual earnings per share reported by Bristol-Myers Squibb Company for the previous quarter, Wall Street now forecasts 23.53% EPS growth.

Analysts await PDF Solutions, Inc. (NASDAQ:PDFS) to report earnings on April, 26. They expect $-0.02 earnings per share, down 200.00% or $0.04 from last year’s $0.02 per share. After $-0.08 actual earnings per share reported by PDF Solutions, Inc. for the previous quarter, Wall Street now forecasts -75.00% EPS growth.

Investors sentiment increased to 1.45 in 2017 Q4. Its up 0.04, from 1.41 in 2017Q3. It is positive, as 11 investors sold PDFS shares while 31 reduced holdings. 35 funds opened positions while 26 raised stakes. 28.11 million shares or 8.41% more from 25.93 million shares in 2017Q3 were reported. Harber Asset Ltd Limited Liability Company invested in 1.89% or 343,399 shares. California State Teachers Retirement System holds 0% or 44,002 shares. Needham Investment Mngmt Limited Company stated it has 972,500 shares or 4.06% of all its holdings. Bancshares Of Ny Mellon Corp has invested 0% in PDF Solutions, Inc. (NASDAQ:PDFS). Brown Advisory owns 19,466 shares. Ameriprise Fincl Incorporated accumulated 140,321 shares. Moreover, Bnp Paribas Arbitrage has 0% invested in PDF Solutions, Inc. (NASDAQ:PDFS). Aperio Gru Ltd Co has 0% invested in PDF Solutions, Inc. (NASDAQ:PDFS) for 13,781 shares. Tiaa Cref Ltd Limited Liability Company, a New York-based fund reported 67,717 shares. State Board Of Administration Of Florida Retirement Systems holds 0% of its portfolio in PDF Solutions, Inc. (NASDAQ:PDFS) for 14,502 shares. Cardinal Cap Mngmt Ct holds 0.97% or 1.58 million shares. 163,770 were accumulated by Rice Hall James And Associate Limited Company. State Of Alaska Department Of Revenue stated it has 0% of its portfolio in PDF Solutions, Inc. (NASDAQ:PDFS). 8,880 are held by Jpmorgan Chase And Co. Schwab Charles Mngmt stated it has 127,014 shares or 0% of all its holdings.

PDF Solutions, Inc. (NASDAQ:PDFS) Institutional Positions Chart